Eli Lilly's Foundayo Launch Aims to Redefine Access to Weight-Loss Drugs

Eli Lilly's new oral GLP-1 drug Foundayo launches widely in the US, requiring no refrigeration and available via Amazon Pharmacy, with Medicare coverage expanding in July 2026.

Eli Lilly’s new once-daily weight-loss pill, Foundayo, is now widely available across the United States. The oral GLP-1 medication, approved by the FDA on April 1, 2026, hit the market on April 9, marking a strategic push to capture a broader patient base through unprecedented distribution channels.

A key differentiator for Foundayo is its lack of a refrigeration requirement, a logistical hurdle for injectable rivals like Mounjaro and Zepbound. This stability enables a vast and immediate retail network. Patients can now obtain the drug through Amazon Pharmacy, which offers same-day delivery in nearly 3,000 U.S. cities with plans to expand to about 4,500 by the end of 2026. It is also available via LillyDirect, telehealth providers such as Ro and Weight Watchers, and the GoodRx network encompassing over 70,000 pharmacies. Select One Medical clinics further offer physical kiosks for pickup.

Financially, the company appears prepared for strong demand. Eli Lilly reported a $1.5 billion inventory stockpile in February, nearly triple the prior year's level, aiming to avoid the supply shortages that plagued earlier GLP-1 injectables.

Pricing is set to be competitive. The cash price for the lowest dose starts at $149 per month, matching Novo Nordisk’s oral Wegovy. With a manufacturer savings card and private insurance, the monthly out-of-pocket cost can drop to as low as $25. A significant demand catalyst is expected from July 1, 2026, when Medicare Part D expands coverage for GLP-1 medications, capping monthly costs for eligible patients at a maximum of $50.

The drug's clinical profile, based on the ATTAIN-1 study, shows promise. Participants on the highest dose (36 mg) lost an average of 12.4% of their body weight over 72 weeks, compared to minimal weight loss in the placebo group. Foundayo also offers a practical edge over some competitors, as it can be taken without restrictions related to food, water intake, or time of day.

The launch occurs in a favorable market context. Lilly’s established GLP-1 drugs, Mounjaro and Zepbound, generated combined revenue of $36 billion in 2025. Overall corporate revenue surged 43% to $19.3 billion in the fourth quarter of that year. Wall Street has high expectations for the new product, with analysts polled by FactSet forecasting Foundayo sales of approximately $1.55 billion for 2026, on a growth trajectory toward nearly $14.8 billion by 2030.

Investor focus now shifts to the company’s first-quarter 2026 earnings report due on April 30. The results will provide the first concrete signal of Foundayo’s market reception; sales approaching $500 million for the partial launch quarter would suggest the oral GLP-1 market is expanding faster than anticipated. However, the stock has retreated about 12% year-to-date, trading roughly 16% below its 52-week high of €959.50. While Foundayo’s potential is significant, the earnings conference will likely also address persistent headwinds, including pricing pressure from the Trump administration, potential pharmaceutical tariffs, and a full-year guidance that disappointed some on Wall Street.